AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Crohn's DiseasePRNewsWire • 07/27/22
European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative ColitisPRNewsWire • 07/26/22
AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 ConferencePRNewsWire • 07/25/22
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of GlaucomaPRNewsWire • 07/20/22
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Business Wire • 07/18/22
The 7 Highest-Yielding Dividend Aristocrats You Can Buy Now and Hold Forever24/7 Wall Street • 07/18/22
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of MigrainePRNewsWire • 07/18/22